Edwin Romel de Leon, MD
Psychiatry · The Dalles, ORNPI 1871735464
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 29.7% of the total. Reporting peaked in 2019 at $532 and has fallen 79.3% since, to $110 in 2022. Among psychiatry clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$221
- Alkermes, Inc.$187
- Johnson & Johnson$150
- Sunovion Pharmaceuticals Inc.$144
- Ironshore Pharmaceuticals Inc.$17
- Lundbeck LLC$14
- plus $12 from 1 others
What the payments were for
- Food & beverage$745100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 18 | $221 |
| Alkermes, Inc. | 5 | $187 |
| Johnson & Johnson | 10 | $150 |
| Sunovion Pharmaceuticals Inc. | 12 | $144 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $14 |
| Boston Scientific | 1 | $12 |
How this compares
$745 in reported general payments places this provider in the 90th percentile of 366 psychiatry providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trazodone Hcl | 17 | $204 |
| Quetiapine Fumarate | 18 | $158 |
| Olanzapine | 11 | $91 |
| Fluoxetine Hcl | 11 | $46 |
| Zolpidem Tartrate | 12 | $30 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in The Dalles
- Daniel FerberThe Dalles$595
- Andrew WilliamsBeaverton$84K
- Jacqueline AmatoMedford$27K
- Alisha MorelandPortland$20K
- Leigh Anne BresslerPortland$15K
- John LipkinEugene$15K
- Alfred LewyPortland$9K
- Hernan SchmidtEugene$8K
- Anca Maria BejenaruPortland$6K
- Erik VanderlipLake Oswego$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.